Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy Volunteers

Lilly

Status and phase: Completed; Phase 2

Conditions: Alzheimer's Disease

Treatments: Drug: LY2062430; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT00329082

H8A-MC-LZAJ

6649

Details and patient eligibility

About

To study the safety of LY2062430 in patients with mild-to-moderate Alzheimer's disease and in healthy volunteers.

Enrollment: 25 patients

Sex: All

Ages: 50+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• At least 50 years of age and diagnosed with mild to moderate Alzheimer's disease or healthy volunteers
• fluent in reading and speaking English
• AD patients must have a reliable study partner who will be in frequent contact with the patient and comply with protocol requirements
• AD patients who have received AChEIs or memantine for at least 4 months and on stable therapy for at least 2 months prior to starting study drug

Exclusion criteria

• Have a history of serious infectious disease affecting the brain, head trauma, cancer, drug or alcohol abuse in the past 5 years
• Have serious or uncontrolled health problems or laboratory tests
• Multiple or severe drug allergies
• Prior participation in an active immunization study

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

25 participants in 5 patient groups, including a placebo group

1

Experimental group

Treatment:

Drug: LY2062430

2

Experimental group

Treatment:

Drug: LY2062430

3

Experimental group

Treatment:

Drug: LY2062430

4

Experimental group

Treatment:

Drug: LY2062430

5

Placebo Comparator group

Treatment:

Drug: Placebo